Bala Mohan 4
4 · Mersana Therapeutics, Inc. · Filed Oct 28, 2025
Insider Transaction Report
Form 4
Bala Mohan
SVP, Chief Development
Transactions
- Exercise/Conversion
Common Stock
2025-10-25+250→ 2,999 total - Exercise/Conversion
Restricted Stock Unit
2025-10-25−250→ 0 total→ Common Stock (250 underlying) - Sale
Common Stock
2025-10-27$9.90/sh−77$762→ 2,922 total
Footnotes (5)
- [F1]Represents shares of common stock received upon vesting of the restricted stock units ("RSUs") awarded to the Reporting Person on October 25, 2021.
- [F2]Amounts reported in this Form 4 reflect the one-for-twenty-five reverse stock split effected by the Issuer on July 25, 2025.
- [F3]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- [F4]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F5]Fully vested as of October 25, 2025.